Filing Flows › Tempus AI (TEM) › Guidance & outlook
Tempus AI (TEM) guidance and outlook
Tempus AI (TEM) raised its guidance on Nov 2, 2026: Revenue $1.6B for FY2026; EBITDA $65.0M for FY2026; Revenue +25% for FY2026. Tempus AI's 10-Q filed Nov 2, 2026 makes 29 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $1.6B | reaffirmed |
| EBITDA | FY2026 | $65.0M | reaffirmed |
| Revenue | FY2026 | +25% | reaffirmed |
From the earnings release filed Nov 2, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 2, 2026
- We aim to help physicians find the best therapies for their patients, help pharmaceutical and biotechnology companies make the best drugs possible, and enable patients to access emerging therapies and clinical trials when appropriate.
- Under the terms of the agreement, we will acquire all outstanding shares of Personalis not already owned by us at a price of $16.25 per common share, representing a total enterprise value of $1.5 billion.
- The consideration is planned to consist entirely of our Class A common stock; however, we may elect to pay up to 50% of the aggregate consideration in cash.
- We expect to use the remaining net proceeds from the 2026 Offering for general corporate purposes, which may include acquisitions or strategic investments in complementary businesses or technologies, working capital, operating expenses, capital expenditures and repayment of additional indebtedness.
- Pursuant to the MSA, (i) we will ensure that Pathos develops, and we provide AstraZeneca with, a Foundation Model which has been developed, validated, and maintained using de-identified datasets contributed by us, (ii) the Foundation Model will be developed, validated, and maintained by Pathos, (iii) AstraZeneca has paid us a fee of $35.0 million, and (iv) a syndicate of investors including AstraZeneca will…
- We believe there are several important factors that have impacted and that we expect will impact our operating performance and results of operations.
- We expect to maintain high levels of investment in product innovation over the coming years as we continue to develop new laboratory assays, develop algorithms, and expand our Platform into new disease areas.
- Our ability to develop new products, obtain regulatory approvals when required, launch them into the market, and drive adoption of these products by our customers will continue to play a key role in our results.
- We will continue to make significant investments in our Platform to continually improve our user experience and allow us to generate, ingest and structure data more efficiently as we expand our offerings.
- We expect to maintain high levels of investment in our technology over the coming years as we continue to develop new features to support our current and future business needs.
- Our ability to execute on the development of such technology will continue to play a key factor in our results.
- We will continue to invest significantly in various efforts aimed at improving our average reimbursement, including performing clinical studies to generate evidence of clinical utility, seeking regulatory approval for our tests, and opening additional lab locations.
Tempus AI's latest quarter
Tempus AI, Q3 2026: revenue $412M (+23% year over year), operating margin -13.8%, net loss $14.9M, operating cash flow $9.2M. The chart follows the revenue to costs, profit and cash.
Questions
Did Tempus AI raise or lower its guidance?
Tempus AI (TEM) raised its guidance on Nov 2, 2026: Revenue $1.6B for FY2026; EBITDA $65.0M for FY2026; Revenue +25% for FY2026.
What does Tempus AI expect?
We aim to help physicians find the best therapies for their patients, help pharmaceutical and biotechnology companies make the best drugs possible, and enable patients to access emerging therapies and clinical trials when appropriate. Under the terms of the agreement, we will acquire all outstanding shares of Personalis not already owned by us at a price of $16.25 per common share, representing a total enterprise value of $1.5 billion. The consideration is planned to consist entirely of our Class A common stock; however, we may elect to pay up to 50% of the aggregate consideration in cash.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.